298 related articles for article (PubMed ID: 18585943)
1. Homology models of the mutated EGFR and their response towards quinazoline analogues.
Kotra S; Madala KK; Jamil K
J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
[TBL] [Abstract][Full Text] [Related]
2. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
Rajasekaran R; Sethumadhavan R
Appl Biochem Biotechnol; 2010 Mar; 160(6):1723-33. PubMed ID: 19455431
[TBL] [Abstract][Full Text] [Related]
3. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
4. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
[TBL] [Abstract][Full Text] [Related]
5. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
[TBL] [Abstract][Full Text] [Related]
7. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
[TBL] [Abstract][Full Text] [Related]
9. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Huang Y; Rizzo RC
Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
[TBL] [Abstract][Full Text] [Related]
10. Construction and validation of a RET TK catalytic domain by homology modeling.
Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
[TBL] [Abstract][Full Text] [Related]
12. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
[TBL] [Abstract][Full Text] [Related]
13. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
[TBL] [Abstract][Full Text] [Related]
14. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
San Juan AA
Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
[TBL] [Abstract][Full Text] [Related]
15. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
17. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
18. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
[TBL] [Abstract][Full Text] [Related]
19. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
Kitano Y; Suzuki T; Kawahara E; Yamazaki T
Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]